Recent management of T2D, obesity and the MetS has been transformed by such (second‐generation) glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) as liraglutide and semaglutide, and, more recently, dual agonists of GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP) receptors, such as tirzepatide. Here, GLP1R is linked to metabolic syndrome.